摘要:
It is intended to provide pergolide-containing transdermal preparations having reduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.
摘要:
A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 μm and, superimposed thereon, a drug containing layer. The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug containing layer. Additionally, the pressure sensitive adhesive layer contains an adhesive resulting from the polymerization of vinyl acetate or N-vinyl-2-pyrrolidone and a C8 alkyl (meth)acrylate as essential monomers. Thus, there is provided a cover material that, when a patch medicated with, for example, mesylic acid pergolide is fixed on diseased part, such as, a part of the skin, by covering the patch, is capable of reducing irritation, etc. on the diseased part.